corresponding in size to 41kDa (ERd5P). There was a significant correlation between coexpression of ERd5P and the splice variant mRNA lacking exon 5 (ERd5M) examined by corresponding in size to 52kDa (ERd7P) were observed in spite of the splice variant mRNA lacking exon 7 (ERd7M) being co-expressed with wild-type mRNA. Our results suggest that ERd5P persists and is stable in a large proportion of samples of human breast cancer tissue, whereas ERd7P is not. The functional difference between ERwtP and ERd5P has yet to be established, and its discovery may demonstrate the importance of ERd5P for anti-estrogen resistance in human breast cancer.
Introduction
It is well known that estrogen and its receptor are significantly related to the development and growth of human breast cancer; advanced studies about the receptor Send reprint requests to: Masao Hori MD, 6528 Koibuchi, Tomobe, Nishi-ibaraki, Ibaraki 309-1703, Japan. E-mail: ms-hori@chubyoin.preff.ibaraki.jp.
ANNALS OF Cancer
Research and Therapy mRNAs is not uncommon in human breast disease (Hori, Katano, et al., 1998) , it is not clear whether the corresponding variant proteins persist and are stable. In the present mRNA in human breast cancer tissue. Our current investigation is directed at identifying ERd5P as well as ERd5M.
Materials and Methods

Specimens
Frozen tissues of invasive ductal carcinoma were obtained from 80 female patients, and the MCF-7 cell line (Dainippon Pharmaceutical Co, Ltd, Osaka, Japan) was
Western blot analysis
Cell lysis and Western blot analysis of each sample and cell line was performed as described previously (Sambrook, Fritsch, 1989) . The protein lyzate was electrophoresed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitro-cellulose membranes. After blocking with Tris-buffered saline, the M7047; DAKO Japan, Kyoto, Japan). The specific complex was detected by the enhanced chemiluminescence Western blot protocol using an ECL detection kit (RPN2209; Amersham, Aylesbury, UK).
Enzyme immunoassay (EIA) procedure protein was measured using a commercial EIA kit (Abbott Diagnostic Laboratories, North Chicago, IL, USA), as described elsewhere (Saccani-Jotti, Johnston, Salter et al., 1994) . Values of over 14.0 fmol/mg protein were considered to be positive.
Reverse transcription polymerase chain reaction (RT-PCR) procedure
A part of each sample was homogenized and the total RNA was isolated using (Table I ). In the 68 cases that expressed ERwtP, there was a significant difference in ERa positivity between the group that exhibited ERd5P co-expression and that which expressed ERwtP alone (Table II) .
All of the 80 samples and the MCF-7 cell line exhibited 479-base-pair (bp) (Table III) . cancer cell lines (Hori, Katano et al., 1998) . Gallacchi, Schoumacher et al. (1998) reported that the proportion of ERd5M in total ER a mRNA was higher in recurrent cancer than in primary breast cancer. Fujimoto, Ichigo et al. (1997) suggested that ERd5M abundance might be a useful indicator of metastatic potency in gynecological cancers. However, it is unclear whether these aberrant forms correlate directly with the anti-estrogen resistance of breast cancer. From the viewpoint of mRNA levels, our results did not support clearly the correlation between splice variants and anti-estrogen resistance (Hori, Katano et al., 1998) . However, from the viewpoint of protein levels, the present results showed that ERd5P translated from ERd5M persisted in many cases, whereas ERd7P did not and later became less stable. Although we did not examine any other splice variant mRNAs and could not deny the presence of extremely low amounts of any other variant proteins, our results suggest that ERd5P is the main variant protein that persists in human breast cancer. Although several authors have pointed out the abnormal functions of splice variant mRNAs (Chaidarun and Alexander 1998; Rea and Parker 1996; Wang and Miksicek 1991) , further study is required to pursue the functional difference between ERwtP and ERd5P. The results of such a study may demonstrate the importance of ERd5P for anti-estrogen resistance in human breast cancer.
